Difference between revisions of "Talk:ABCC2"
Jump to navigation
Jump to search
(→Abstract: new section) |
(No difference)
|
Revision as of 00:30, 19 May 2026
Abstract
Papillary renal cell carcinoma with ABCC2 brush border immunoreactivity confers resistance to cabozantinib, highlighting the therapeutic potential of ABCC2 inhibition - CKCis 2026